Reuters logo
BRIEF-Crossject gets authorization to conduct study on bioequivalence of Zeneo Midazolam
March 6, 2017 / 7:37 AM / in 8 months

BRIEF-Crossject gets authorization to conduct study on bioequivalence of Zeneo Midazolam

March 6 (Reuters) - Crossject SA:

* Gets authorization to conduct study on bioequivalence of Zeneo Midazolam Source text for Eikon: Further company coverage: (Gdynia Newsroom)

Our Standards:The Thomson Reuters Trust Principles.
0 : 0
  • narrow-browser-and-phone
  • medium-browser-and-portrait-tablet
  • landscape-tablet
  • medium-wide-browser
  • wide-browser-and-larger
  • medium-browser-and-landscape-tablet
  • medium-wide-browser-and-larger
  • above-phone
  • portrait-tablet-and-above
  • above-portrait-tablet
  • landscape-tablet-and-above
  • landscape-tablet-and-medium-wide-browser
  • portrait-tablet-and-below
  • landscape-tablet-and-below